Thyme Care’s Series D round included participation from CVS Health Ventures, Foresite Capital, Morgan Health and Humana. In total, it has raised $275 million. The post Thyme Care Banks $97M to Accelerate Value-Based Cancer Care appeared first on MedCity News.
At a time of intense change in healthcare, radiology is being swept up like the other specialties
Leader of one of the largest hospital-at-home programs calls it ‘one of the most disruptive elements of care delivery that we’ve had in a generation’
The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia. The post Neurocrine Bio Drug Licensed…
All Marketplace plans have free preventive benefits to help keep you healthy and avoid more serious illnesses. Talk with your doctor to figure out which services are right for you. Remember, services are only free if you get them from a provider in your plan’s network. Image What preventive services could I get? Some common services include:…
Major healthcare providers like Kaiser Permanente and Mayo Clinic are investing heavily in AI
Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment. The post Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics appeared first on MedCity…
Here is a selection of recent executive hires, exits, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.
By MATTHEW HOLT I have been trying hard to suppress this line of thought but when I woke up in the middle of the night with this piece basically fully formed in my head I couldn’t not write it. Yes I might lose some friends, but someone in health tech has to say this. Last…
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022. The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.